Eugene Quaye, DO
Pulmonary Disease · Tulsa, OKNPI 1659804508
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.2%), education and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Intuitive Surgical at 39.4% of the total. Reporting peaked in 2024 at $4,128 and has fallen 70.1% since, to $1,236 in 2025.
Across 153 payments — averaging $41.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Olympus Corporation Of The Americas$1K
- AstraZeneca$696
- Sanofi$473
- GSK$317
- Viatris Specialty LLC$223
- plus $854 from 19 others
What the payments were for
- Travel & lodging$1,18018%
- Food & beverage$2,63641%
- Education$2,58940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 2 | $2,522 |
| Olympus Corporation Of The Americas | 20 | $1,319 |
| AstraZeneca | 33 | $696 |
| Sanofi | 22 | $473 |
| GSK | 24 | $317 |
| Viatris Specialty LLC | 13 | $223 |
| Regeneron Healthcare Solutions, Inc. | 9 | $198 |
| United Therapeutics Corporation | 4 | $99 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Abiomed | 2 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| AbbVie | 3 | $54 |
| Verona Pharma, Inc. | 3 | $46 |
| Baxter Healthcare | 2 | $39 |
| Amgen | 2 | $33 |
| Shionogi Inc | 1 | $23 |
| Shire North American Group Inc | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Gilead | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Merck | 1 | $15 |
| Inogen, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,405 in reported general payments places this provider in the 70th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 118 | $89,389 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $40,174 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $26,512 |
| Spiriva RespimatTiotropium Bromide | 34 | $19,615 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,635 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,382 |
| Varenicline Tartrate | 21 | $3,575 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,204 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $2,159 |
| Ventolin HfaAlbuterol Sulfate | 17 | $1,337 |
| Roflumilast | 21 | $1,216 |
| Azelastine Hcl | 35 | $873 |
| Fluticasone Propionate | 22 | $424 |
| Omeprazole | 28 | $413 |
| Montelukast Sodium | 40 | $335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $317 | $100,406148 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $20 | $46,12877 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $696 | $43,37864 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Tulsa
- Jennifer BierachTulsa$141K
- Hassan AbouhouliTulsa$103K
- Grace KennedyTulsa$57K
- Walter BoomerTulsa$43K
- Emil SchelbarTulsa$20K
- Andrew GottehrerTulsa$16K
- Bradley EdgingtonTulsa$12K
- Habiba HussainTulsa$10K
- Conner MoslanderTulsa$9K
- Pratyaksha SankhyanTulsa$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.